Evidence map›Paper›PMID 40404862›Full record

ArticleNPJ precision oncology2025

Mitigating bias in prostate cancer diagnosis using synthetic data for improved AI driven Gleason grading.

Derek J Van Booven, Cheng-Bang Chen, Oleksandr N Kryvenko, Sanoj Punnen, Victor Sandoval, Sheetal Malpani, Ahmed Noman, Farhan Ismael, Yujie Wang, Rehana Qureshi and 2 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Derek J Van BoovenJohn P Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, USA.
Cheng-Bang ChenDepartment of Industrial and Systems Engineering, University of Miami, Miami, FL, USA.
Oleksandr N KryvenkoDepartment of Pathology, Miller School of Medicine, University of Miami, Miami, FL, USA.
Sanoj PunnenDesai & Sethi Institute of Urology, Miller School of Medicine, University of Miami, Miami, FL, USA.
Victor SandovalHospital Valentin Gomez Farias, Universidad de Guadalajara, Guadalajara, Mexico.
Sheetal MalpaniDepartment of Pathology, Miller School of Medicine, University of Miami, Miami, FL, USA.
Ahmed NomanDow University of Health Sciences, Karachi, Sindh, Pakistan.
Farhan IsmaelDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas city, KS, USA.
Yujie WangDepartment of Industrial and Systems Engineering, University of Miami, Miami, FL, USA.
Rehana QureshiDepartment of Pathology, Miller School of Medicine, University of Miami, Miami, FL, USA.
Joshua M HareDepartment of Medicine, Miller School of Medicine, University of Miami, Miami, FL, USA.
Himanshu AroraJohn P Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, USA. Hxa287@miami.edu.

Funding

1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical TrialUH3HL148318 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI BERGER, STUART, HARE, JOSHUA M · 2021 to 2024
$3.5M
The Rigor and Clinical Utility of PSMA Enriched Extracellular Vesicles for Prostate Cancer DetectionR01CA272766 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SANDRA M GASTON, Alan Pollack · 2023 to 2026
$1.9M
NCI NIH HHS R01CA272766NHLBI NIH HHS UH3HL148318Scott R. MacKenzie Foundation 000-0000ULink Miami PG013269
6 · The paper itself

Abstract

Prostate cancer (PCa) is a leading cause of cancer-related mortality in men, with Gleason grading critical for prognosis and treatment decisions. Machine learning (ML) models offer potential for automated grading but are limited by dataset biases, staining variability, and data scarcity, reducing their generalizability. This study employs generative adversarial networks (GANs) to generate high-quality synthetic histopathological images to address these challenges. A conditional GAN (dcGAN) was developed and validated using expert pathologist review and Spatial Heterogeneous Recurrence Quantification Analysis (SHRQA), achieving 80% diagnostic quality approval. A convolutional neural network (EfficientNet) was trained on original and synthetic images and validated across TCGA, PANDA Challenge, and MAST trial datasets. Integrating synthetic images improved classification accuracy for Gleason 3 (26%, p = 0.0010), Gleason 4 (15%, p = 0.0274), and Gleason 5 (32%, p < 0.0001), with sensitivity and specificity reaching 81% and 92%, respectively. This study demonstrates that synthetic data significantly enhances ML-based Gleason grading accuracy and improves reproducibility, providing a scalable AI-driven solution for precision oncology.

Identifiers

PMID40404862
PMCPMC12098719

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.